Cargando…
Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages
Psoriasis is a common chronic inflammatory skin disease mainly characterized by keratinocyte hyperproliferation and massive infiltration of inflammatory immune cells. Acitretin (ACT), an FDA-approved first-line systemic drug for psoriasis treatment, could suppress the proliferation of keratinocytes...
Autores principales: | Lan, Jiajia, Li, Yuce, Wen, Jingjing, Chen, Yu, Yang, Jing, Zhao, Liang, Xia, Yuting, Du, Hongyao, Tao, Juan, Li, Yan, Zhu, Jintao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777251/ https://www.ncbi.nlm.nih.gov/pubmed/35071218 http://dx.doi.org/10.3389/fbioe.2021.816757 |
Ejemplares similares
-
Synthesis of Dextran–Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity
por: Yee, Eugene M. H., et al.
Publicado: (2019) -
Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer
por: Deng, Guozhen, et al.
Publicado: (2023) -
Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis
por: Li, Ning, et al.
Publicado: (2022) -
Low Molar Mass Dextran: One-Step Synthesis With Dextransucrase by Site-Directed Mutagenesis and its Potential of Iron-Loading
por: Wang, Tingting, et al.
Publicado: (2021) -
Recent Advances of Pullulan and/or Dextran-Based Materials for Bone Tissue Engineering Strategies in Preclinical Studies: A Systematic Review
por: Ahmed Omar, Naïma, et al.
Publicado: (2022)